Recruiting

New medication with radiation therapy for prostate cancer recurrence after surgery

Plain-English translation of NCT06305832 on ClinicalTrials.gov ↗ · Source last updated March 2024 · Translation generated June 2026 · How we translate trials

Read our Prostate Cancer research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called to see if it works better when combined with standard hormone therapy and radiation therapy for men whose prostate cancer has returned after surgery. Right now, doctors use hormone therapy and radiation together as the standard treatment. Researchers want to know if adding this medication to that standard combination can improve outcomes and help more patients.

After prostate surgery, some men's cancer comes back, even though scans look normal—detected only by rising blood markers. Current treatments help, but doctors are looking for ways to improve success rates and give patients better long-term results.

Do you qualify?

You likely qualify if…

you are at least 40 years old and male
you had surgery to remove your prostate and were diagnosed with prostate adenocarcinoma
your PSA blood marker has risen twice in a row (at least 2 weeks apart) and is above 0.2, showing biochemical recurrence
scans (bone scan, CT, or MRI) show no visible local recurrence or spread to distant sites
you have one or more risk factors, such as an aggressive tumor grade, high PSA at recurrence, rapid PSA growth, or an advanced surgical stage
you are in overall good health with a life expectancy of at least 10 years and acceptable blood work and heart function

You likely don't qualify if…

you have previously received hormone therapy or pelvic radiation therapy for prostate cancer
your PSA blood marker is already above 2 ng/ml at the time of recurrence
you have a history of seizures or have had a stroke or serious head injury in the past year
you have had a heart attack, severe chest pain, heart failure, or dangerous heart rhythm problems in the past 6 months
you are allergic to rezvilutamide or cannot swallow pills or have severe chronic diarrhea that affects medicine absorption

What participation looks like

You will be randomly assigned to receive either the new medication plus hormone therapy and radiation, or hormone therapy and radiation alone. The medication (if assigned) is taken by mouth in cycles lasting 28 days each, for a total of 6 cycles. You will also receive standard radiation therapy to the prostate bed according to your doctor's plan. Throughout the trial, you will have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working and to check for any side effects.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(2 sites)

China

Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu